1	- VOLUME 4 -
2	IN THE UNITED STATES DISTRICT COURT IN AND FOR THE DISTRICT OF DELAWARE
3	NOVARTIS PHARMACEUTICALS : CIVIL ACTION
4	CORPORATION and NOVARTIS : AG, :
5	Plaintiffs, : :
6 7	vs. : : BRECKENRIDGE :
8	PHARMACEUTICALS INC., : NO. 14-1043 (RGA) Defendant. :
9	: CIVIL ACTION NOVARTIS PHARMACEUTICALS :
LO	CORPORATION and NOVARTIS : AG, : Plaintiffs, :
L1	vs.
L2	ROXANE LABORATORIES, :
L3	INC., : NO. 14-1196 (RGA)
L4 L5	:: NOVARTIS PHARMACEUTICALS : CIVIL ACTION CORPORATION and NOVARTIS :
16	AG, : Plaintiffs, :
L7	vs. :
L8	: PAR PHARMACEUTICAL, : NO. 14-1289 (RGA)
L9	INC., : Defendant.
20	Wilmington, Delaware
21	Thursday, September 1, 2016 8:30 o'clock, a.m.
22	
23	BEFORE: HONORABLE RICHARD G. ANDREWS, U.S.D.C.J.



PROCEEDINGS
(Proceedings commenced in the courtroom,
beginning at 8:30 a.m.)
THE COURT: All right. Good
morning. Please be seated. Let's continue.
MR. ZULLOW: May we call our next
witness?
THE COURT: Yes.
MR. ZULLOW: Defendants call Dr.
Tullius to the stand.
THE COURT: All right.
MR. ZULLOW: Dr. Tullius is an
expert in transplant surgery and
immunosuppression and he'll be testifying about
the invalidity of the '124 and '518 patents and
he'll provide some information about what was
known in the art in 1992, October of 1992.
THE COURT: Okay.
STEFAN TULLIUS, having been
duly sworn as a witness, was examined
and testified as follows
MR. ZULLOW: Your Honor, may I



1	BY MR. LOH:
2	Q. As of today, patients will better
3	adhere to an immunosuppressant drug regimen in
4	which the drugs can be coadministered at the
5	same time; is that correct?
6	A. Can you please repeat the
7	question?
8	Q. As of today, patients will better
9	adhere to an immunosuppressant drug regimen in
10	which the drugs can be co-administered at the
11	same time?
12	A. Correct.
13	Q. By contrast, taking drugs four
14	hours apart will not result in a treatment
15	regimen that you want?
16	A. That will be much more difficult
17	for a patient to take this treatment, yes.
18	${ t Q.}$ Dr. Tullius, I want to leave the
19	'772 patent behind now and talk about the '518
20	and '124 patents. Okay?
21	A. Mm-hmm.
22	Q. And before we begin this
23	discussion of the '518 and '124 patents, you
24	understand that a person of ordinary skill in

